Findings

What do systematic reviews say?

1 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

Failure to induce remission at 10 weeks · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce remission at 10 weeks compared with placebo (high certainty).

2 findings from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.91 [0.81, 1.01]
1 study · 905 participants
High
Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.85 [0.78, 0.92]
2 studies · 1414 participants
High